Proposed PMPRB regulations requires focused dialogue with all players
Canada needs an approach that balances pricing considerations with the need to encourage investment, foster innovation, and most of all, ensures Canadians have timely access to the most innovative, life-saving new medicines.
In December the federal government formally announced it was delaying the implementation of the Patented Medicine Prices Review Board (PMPRB)’s regulatory changes. There were two reasons stated for the delay. First, it would allow all parties—including the government and the pharmaceutical indus...
SPONSORED CONTENT
Get Weekend Point of View Newsletter
A round up of the past week’s opinion writers and columnists on Saturdays and Sundays.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
